undamentalytics Newsletter
Sign in

Goodrx Holdings, Inc. cash flow statement

In fiscal 2025, Goodrx Holdings, Inc.'s operations generated $168m of cash; it spent $3.5m on capital projects, leaving free cash flow of $164m. It returned $216m through buybacks.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations4583131179147138184168202
Depreciation and amortisation1014183554108708589
Stock-based pay24397160120105997776
Capital spending1121541144
Free cash flow4482111174143137183164197
Free cash flow after stock pay4378−2861423328488121
Dividends paid1,346————————
Share buybacks——0010210415921685
Shares issued—200—————

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: DOCS vs GDRXGDRX vs PHRGDRX vs OMCLGDRX vs WAY

More: Health Care Technology stocks compared, Health Care sector, rankings of US companies

Figures from Goodrx Holdings, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Goodrx Holdings, Inc.